CELCCelcuity Inc.

Filed with the SEC on September 30, 2026 | Current Price: $76.08 | Today's Change: -4.33%

---

What Happened

Celcuity Inc. filed an 8-K with the SEC on September 30, 2026, disclosing financial results for Q2 FY2026. The company reported a net loss of $36,997,000 and an operating loss of $80,142,000 for the quarter, with basic and diluted earnings per share both coming in at -$1.90. The wide gap between the operating loss and net loss lines — roughly $43 million — suggests meaningful non-operating offsets, though the structured filing data does not itemize these further.

---

Why It Matters

For investors, the headline numbers confirm that Celcuity remains in a significant cash-consumption phase, consistent with a clinical-stage biopharmaceutical company carrying an active and presumably expensive drug development pipeline. The $80.1M operating loss in a single quarter is a substantial figure, signaling that operating expenses — likely dominated by R&D and clinical trial costs — continue to run at an elevated rate. At the same time, the net loss of $37.0M being materially narrower than the operating loss may indicate interest income or other non-operating items providing a partial buffer, though investors should consult the full filing for a complete breakdown. The stock is down 4.33% on the day, suggesting the market is digesting these figures with some caution. Notably, StockWatch initiated coverage of Celcuity on the same date as this filing — September 30, 2026 — which provides additional context for investors seeking deeper analysis of the company's position.

---

Analysis

The divergence between Celcuity's operating loss ($80.1M) and its net loss ($37.0M) is the single most analytically interesting feature of this disclosure. If the gap is driven by interest income — plausible for a company that has raised substantial equity capital and holds a large cash position — it would indicate that Celcuity's balance sheet is providing a meaningful runway cushion, even as operational spending remains aggressive. What to watch next: the rate at which operating losses are running will be the key determinant of how long the company's cash reserves can sustain current trial activities. Investors should monitor any forward guidance or pipeline updates that may accompany or follow this filing, particularly around clinical milestones that could catalyze future financing or partnership discussions. The filing's inclusion of Items 7.01, 8.01, and 9.01 — covering Regulation FD disclosure, other events, and financial exhibits respectively — suggests this may be tied to a presentation or public communication event, which could shed further light on management's current messaging to the market.

---

Disclaimer

This report is a news and informational analysis based solely on data extracted from Celcuity Inc.'s SEC filing and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or a recommendation of any kind. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decision. Past performance is not indicative of future results.

Existing Coverage

StockWatch has full coverage on CELC, published 2026-09-30. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-09-30. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1603454/000119312526408353/celc-20260930.htm